Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone
J Clin Psychiatry 2003;64(suppl 16):41-46
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
The availability of a long-acting injectable atypical
antipsychotic may increase compliance with medication regimens in patients with schizophrenia. Currently,
long-acting risperidone is the only such agent. It is now
available or approved in 33 countries, including Austria,
Germany, Mexico, the Netherlands, New Zealand, and the United Kingdom.